Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.555 USD | +10.29% | +41.12% | -59.63% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-59.63% | 75.43M | |
+4.51% | 111B | |
+11.40% | 105B | |
-12.24% | 22.34B | |
-3.73% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-9.63% | 16.96B | |
+3.12% | 13.7B | |
+36.65% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Canaccord Genuity Initiates Annovis Bio at Buy With $36 Price Target